Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 4:20 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 109 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Vaginosis, Bacterial Clear all
Completed Phase 2 Interventional Results available

A Phase 2 Study of SYM-1219 to Treat Bacterial Vaginosis

NCT02147899
View directory record Official record
Conditions
Bacterial Vaginosis
Interventions
SYM-1219, Placebo
Drug
Lead sponsor
Symbiomix Therapeutics
Industry
Eligibility
18 Years and older · Female only
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
16
States / cities
Birmingham, Alabama • San Diego, California • Clearwater, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2020 · Synced Oct 6, 2026, 4:20 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Oral Encochleated Amphotericin B (CAMB/MAT2203) in the Treatment of Vulvovaginal Candidiasis (VVC)

NCT02971007
View directory record Official record
Conditions
Vulvovaginitis, Yeast Infection, Yeast Infection Vaginal, Candidiasis, Vulvovaginal
Interventions
Oral Encochleated Amphotericin B (CAMB), Fluconazole
Drug
Lead sponsor
Matinas BioPharma Nanotechnologies, Inc.
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
23
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2018 · Synced Oct 6, 2026, 4:20 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A First-in-human Safety Trial of BNT331 Administered as Single Ascending Doses in Healthy Women and as Multiple Ascending Doses in Women Diagnosed With Bacterial Vaginosis

NCT06469164
View directory record Official record
Conditions
Bacterial Vaginosis
Interventions
BNT331, Placebo
Drug · Other
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older · Female only
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
6
States / cities
Birmingham, Alabama • Marrero, Louisiana • Metairie, Louisiana + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 6, 2026, 4:20 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Prospective Data Bank Creation to Study Vaginal Conditions

NCT01829204
View directory record Official record
Conditions
Vulvodynia, Mycoses, Bacterial Vaginosis, Preterm Labor
Interventions
Not listed
Lead sponsor
Texas Tech University Health Sciences Center
Other
Eligibility
21 Years to 75 Years · Female only
Enrollment
550 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2027
U.S. locations
1
States / cities
Midland, Texas
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Oct 6, 2026, 4:20 AM EDT
Completed Phase 3 Interventional Results available

A Multi-center, Double-blind, Randomized Study, Comparing Clindamycin Phosphate Vaginal Cream 2% (Watson Laboratories, Inc.) to Clindesse® (Ther-Rx™, Clindamyin Phosphate Vaginal Cream 2%) and Both Active Treatments to a Placebo Control in the Treatment of Bacterial Vaginosis in Non-pregnant Women

NCT02210689
View directory record Official record
Conditions
BACTERIAL VAGINOSIS, Signs and Symptoms to be Evaluated and Recorded Include, Vaginal Discharge Color, Odor, and Consistency, Vulvovaginal Itching and Irritation (Subjective) Absent, Mild, Moderate, or Severe, Vulvovaginal Inflammation (Objective) Absent, Mild, Moderate, or Severe
Interventions
clindamycin phosphate vaginal cream 2%, placebo
Drug · Other
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
604 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
15
States / cities
Birmingham, Alabama • La Mesa, California • San Diego, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2020 · Synced Oct 6, 2026, 4:20 AM EDT
Completed Phase 2 Interventional

MGCD290 and Fluconazole Versus Fluconazole Alone for the Treatment of Moderate to Severe Vulvovaginal Candidiasis

NCT01497223
View directory record Official record
Conditions
Vulvovaginal Candidiasis
Interventions
MGCD290
Drug
Lead sponsor
MethylGene Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
19
States / cities
Birmingham, Alabama • San Diego, California • Lake Worth, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2013 · Synced Oct 6, 2026, 4:20 AM EDT
Withdrawn Phase 2 Interventional

A Pilot Study of Oral Tinidazole for Women With Recurrent Bacterial Vaginosis

NCT00324142
View directory record Official record
Conditions
Recurrent Bacterial Vaginosis
Interventions
Oral tinidazole
Drug
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years to 45 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 2, 2012 · Synced Oct 6, 2026, 4:20 AM EDT
Completed Early Phase 1 Interventional

Vaginal lIve Biotherapeutic RANdomized Trial

NCT06135974
View directory record Official record
Conditions
Bacterial Vaginosis
Interventions
LC106, LC115, Placebo, Metronidazole Oral
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 25, 2025 · Synced Oct 6, 2026, 4:20 AM EDT
Terminated Phase 4 Interventional Results available

A Randomized Controlled Trial of Treatment of Bacterial Vaginosis

NCT04578015
View directory record Official record
Conditions
Bacterial Vaginoses
Interventions
Metronidazole, Placebo
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 15, 2023 · Synced Oct 6, 2026, 4:20 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment

NCT03059992
View directory record Official record
Conditions
Invasive Candidiasis, Mucocutaneous Candidiasis, Coccidioidomycosis, Histoplasmosis, Blastomycosis, Chronic Pulmonary Aspergillosis, Allergic Bronchopulmonary Aspergillosis, Invasive Pulmonary Aspergillosis, Recurrent Vulvovaginal Candidiasis, Other Emerging Fungi
Interventions
Ibrexafungerp
Drug
Lead sponsor
Scynexis, Inc.
Industry
Eligibility
18 Years and older
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
20
States / cities
Birmingham, Alabama • Sacramento, California • San Francisco, California + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Oct 6, 2026, 4:20 AM EDT
Completed Phase 2 Interventional Results available

Topical Metronidazole and Miconazole Co-formulated Vaginal Suppositories for Preventing Vaginal Infections in HIV-seronegative Women

NCT01230814
View directory record Official record
Conditions
Bacterial Vaginosis, Candidiasis, Trichomoniasis
Interventions
Neo-Penotran® Forte (active ingredient Metronidazole & Miconazole Nitrate), Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years · Female only
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 6, 2014 · Synced Oct 6, 2026, 4:20 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetic Study in Healthy Lactating Women Exposed to Ibrexafungerp

NCT06954493
View directory record Official record
Conditions
Vulvovaginal Candidiasis, Candida Infection, Vaginal Candidiasis
Interventions
Ibrexafungerp
Drug
Lead sponsor
Scynexis, Inc.
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Rogers, Arkansas
Source: ClinicalTrials.gov public record
Updated Aug 8, 2025 · Synced Oct 6, 2026, 4:20 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Diagnosing Bacterial Vaginosis/Vaginitis (BV) Using the Gynecologene Test Method

NCT02558179
View directory record Official record
Conditions
Vaginosis, Bacterial
Interventions
Not listed
Lead sponsor
American International Biotechnology
Industry
Eligibility
18 Years to 55 Years · Female only
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
4
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Jacksonville, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2016 · Synced Oct 6, 2026, 4:20 AM EDT
Completed Phase 1Phase 2 Interventional

Bioequivalence of Metronidazole Gel, 0.75% in the Treatment of Bacterial Vaginosis

NCT01020396
View directory record Official record
Conditions
Bacterial Vaginosis
Interventions
Metronidazole
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older · Female only
Enrollment
579 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
37
States / cities
Huntsville, Alabama • Fountain Valley, California • Washington D.C., District of Columbia + 22 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2024 · Synced Oct 6, 2026, 4:20 AM EDT
Completed Early Phase 1 Interventional

Impact of Clinician-administered Vaginal Live Biotherapeutic Product

NCT07305844
View directory record Official record
Conditions
Bacterial Vaginosis
Interventions
LC106
Drug
Lead sponsor
Caroline Mitchell
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 6, 2026, 4:20 AM EDT
Completed Phase 4 Interventional

Safety and Tolerability of Metronidazole Gel 1.3%

NCT02392026
View directory record Official record
Conditions
Vaginosis, Bacterial
Interventions
Metronidazole Gel
Drug
Lead sponsor
Insud Pharma
Industry
Eligibility
12 Years to 17 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
8
States / cities
Long Beach, California • Paramount, California • Bardstown, Kentucky + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2023 · Synced Oct 6, 2026, 4:20 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Refining Treatment Options for Trichomonas Vaginalis Infection: A Comparative Analysis of Metronidazole and Secnidazole

NCT06261840
View directory record Official record
Conditions
Trichomonas Vaginitis, Bacterial Vaginitis
Interventions
Metronidazole 500 mg, Secnidazole 2000 MG
Drug
Lead sponsor
Tulane University
Other
Eligibility
18 Years and older
Enrollment
1,200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
4
States / cities
Birmingham, Alabama • North Miami, Florida • New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 6, 2026, 4:20 AM EDT
Recruiting No phase listed Observational

Large Algorithm Setting and Validation Study

NCT07607470
View directory record Official record
Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Infections, Vaginitis, Vaginal Diseases, Genital Diseases, Female, Female Urogenital Diseases, Urogenital Disease, Candidiasis, Mycoses, Vulvovaginitis, Vulvar Diseases, Vaginosis, Bacterial
Interventions
Nanopath Vaginitis Assay, BD Max™ Vaginal Panel, Cepheid Xpert® Xpress MVP, Hologic Aptima® BV Assay, Yeast Culture
Diagnostic Test
Lead sponsor
Nanopath, Inc
Industry
Eligibility
18 Years and older · Female only
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
North Miami, Florida • New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 6, 2026, 4:20 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of SPL7013 Gel to Prevent the Recurrence of Bacterial Vaginosis (BV)

NCT02237950
View directory record Official record
Conditions
Bacterial Vaginosis
Interventions
Metronidazole oral tablets 500mg, 1% SPL7013 Gel, Placebo gel
Drug
Lead sponsor
Starpharma Pty Ltd
Industry
Eligibility
16 Years to 45 Years · Female only
Enrollment
586 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
37
States / cities
Birmingham, Alabama • Montgomery, Alabama • Little Rock, Arkansas + 32 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2019 · Synced Oct 6, 2026, 4:20 AM EDT
Completed No phase listed Observational

Longitudinal Study of Vaginal Flora

NCT00340275
View directory record Official record
Conditions
Vaginal Flora
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
15 Years to 44 Years · Female only
Enrollment
5,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2010
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 6, 2026, 4:20 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Trial of Trimosan Gel Effect on Pessary-associated Bacterial Vaginosis

NCT01471457
View directory record Official record
Conditions
Bacterial Vaginosis
Interventions
Trimo-San gel
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years and older · Female only
Enrollment
184 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Apr 22, 2020 · Synced Oct 6, 2026, 4:20 AM EDT
Terminated Phase 4 Interventional Results available

Postmenopausal Pessary Users: Estrogen Versus Trimosan

NCT03943823
View directory record Official record
Conditions
Vaginosis, Vaginosis, Bacterial, Vaginal Discharge
Interventions
Estrogen vaginal cream, Trimo-San vaginal gel
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
40 Years and older · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 8, 2023 · Synced Oct 6, 2026, 4:20 AM EDT
Completed Phase 3 Interventional Results available

Open-Label Study to Evaluate Safety of A Single Dose of SYM-1219

NCT02452866
View directory record Official record
Conditions
Bacterial Vaginosis
Interventions
SYM-1219
Drug
Lead sponsor
Symbiomix Therapeutics
Industry
Eligibility
12 Years and older · Female only
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
40
States / cities
Birmingham, Alabama • Phoenix, Arizona • Jonesboro, Arkansas + 34 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2021 · Synced Oct 6, 2026, 4:20 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Single Arm Trial of Menstrual Cups Among Economically Vulnerable Women to Reduce Bacterial Vaginosis and STIs

NCT05666778
View directory record Official record
Conditions
Bacterial Vaginosis, Vaginal Microbiome, Chlamydia Trachomatis Infection, Neisseria Gonorrheae Infection, Trichomonas Vaginitis
Interventions
Menstrual Cup
Device
Lead sponsor
Rush University Medical Center
Other
Eligibility
15 Years to 35 Years · Female only
Enrollment
408 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 6, 2026, 4:20 AM EDT